Influenza virus reassortment
US-8945904-B2 · Feb 3, 2015 · US
Influenza virus reassortment method
US9574181B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9574181-B2 |
| Application number | US-201414522747-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 24, 2014 |
| Priority date | May 21, 2010 |
| Publication date | Feb 21, 2017 |
| Grant date | Feb 21, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods for producing reassortant viruses are provided wherein the transcription and/or translation of the hemagglutinin and/or neuraminidase genes are suppressed.
First claim
Opening claim text (preview).
The invention claimed is: 1. A culture comprising: host cells infected with a first influenza viral strain and a second influenza viral strain, wherein the host cells are in contact with a nucleic acid inhibitory agent that preferentially reduces the transcription and/or translation of one or more surface antigens of the first or the second influenza viral strain. 2. The culture of claim 1 , wherein the culture is free of animal derived products. 3. The culture of claim 1 , wherein the culture is free of added antibodies to the one or more surface antigens. 4. The culture of claim 1 , wherein the nucleic acid inhibitory agent is a synthetic antisense oligomer. 5. The culture of claim 1 , wherein the nucleic acid inhibitory agent is a phosphorothioate oligomer (PSO). 6. The culture of claim 1 , wherein the nucleic acid inhibitory agent is a phosphorodiamidate morpholino oligomer (PMO). 7. The culture of claim 1 , wherein the nucleic acid inhibitory agent is selected from the group consisting of: short interfering RNAs (siRNA), double-stranded RNAs (dsRl\fA), micro-RNAs (miRNA), short hairpin RNAs (shRNA), and small interfering DNAs (siDNA). 8. The culture of claim 1 , wherein the culture is an ernbryonated hen egg. 9. The culture of claim 1 , wherein the host cells are mammalian cells or avian cells. 10. The culture of claim 1 , wherein the influenza surface antigens are HA and/or NA.
Assignees
Inventors
Classifications
Virus · CPC title
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title
Applications; Uses · CPC title
Viral antigens · CPC title
against viruses · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9574181B2 cover?
- Methods for producing reassortant viruses are provided wherein the transcription and/or translation of the hemagglutinin and/or neuraminidase genes are suppressed.
- Who is the assignee on this patent?
- Seqirus Uk Ltd
- What technology area does this patent fall under?
- Primary CPC classification C12N7/00. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).